Drug intelligence / Profile preview

Otlertuzumab

Development stage: Discontinued
Lead developer: Emergent BioSolutions
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Otlertuzumab is a humanized anti-CD37 monoclonal antibody designed for the treatment of B-cell malignancies. It binds to CD37, a tetraspanin protein highly expressed on B lymphocytes, and induces cell death through direct cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC). Otlertuzumab was primarily developed for use in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. The drug was originally developed by Emergent BioSolutions.

Other names: otlertuzumabImmunoglobulin anti-human CD antigen CD37 synthetic human-mus musculus fragment tru-016 dimer

Targets

CD37

Beyond the preview

Go deeper on Otlertuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Otlertuzumab.

Explore the full profile